Oil cools, Nvidia gets the wheel

 

The market climbed Tuesday as falling crude and Treasury yields gave technology room to lead without resolving the U.S.-Iran risk hanging over the session.  Semiconductors carried the index advance, but the real action was in company-specific punishment. Dick’s collapsed under Foot Locker’s drag, while Intuit and Zoom slipped after hours despite headline beats. Wednesday’s PCE, GDP, and Nvidia report will test whether lower yields can keep supporting growth stocks.  On Stocks, retail traders crowded into the damage. Dick’s room stayed 98% bullish after a 31% collapse, Zoom’s was 78% bullish after its report, and Intuit traders debated whether the guide reflected weaker growth or simply new stock-comp math.  Today's Briefing: Powered by Stocktwits Community API. After the Bell: Intuit resets its growth yardstick while Zoom’s enterprise rebound meets a soft profit guide.  Stocks: Foot Locker drags Dick’s into a record collapse.  Macro News: Trump’s June filing maps 1,051 portfolio transactions across stocks, ETFs, bonds, and Treasuries.  What's Trending Now on Stocks  P.S. Nvidia is reporting romottow!! NVDA earnings preview: Q2 '27. The Street expects:  EPS: $2.09 expected, up 99.0% YoY from $1.05  Rev: $92.27B expected, up 97.4% YoY from $46.74B  Post-earnings move: ±3.2% typical, last was -1.8% on May 20

AFTER THE BELL Intuit Taxes Its Outlook

Intuit, the company behind TurboTax, QuickBooks, Credit Karma, and Mailchimp, beat Q4 expectations Tuesday but projected slower fiscal 2027 growth as Mailchimp weakness and a new stock-compensation treatment reset the scorecard. Shares extended their regular-session decline after hours.

The RIP: $INTU fell 9% after hours after closing down 3.4%. Adjusted EPS was $4.03 vs. $3.58 consensus, and revenue was $4.35B vs. $4.27B. Fiscal 2027 revenue guidance was $23.28B-$23.51B, representing 9%-10% growth after 14% in fiscal 2026.

QuickBooks and the Big Bets portfolio still did the heavy lifting, but holders now need evidence that 9%-10% growth is a floor, not the new ceiling. Intuit’s Sept. 17 Investor Day must explain Mailchimp’s stall and how much of the apparent EPS reset comes from newly including stock-based compensation. The room’s bullish valuation game starts at $22.88-$23.12 and 22x, which lands near $500 if the new yardstick holds.

The Community Read: The $INTU room is 67% bullish, test the new valuation yardstick ->

"$INTU stop loss raid, no reason this should be dropping, guidance only lower because of $5 a share adjustment for stock base compensation" @the_investor2006

Zoom’s Beat Gets Muted

Zoom, the video meetings and workplace communications provider, beat Q2 expectations Tuesday as enterprise demand accelerated, but its third-quarter profit forecast missed consensus amid competition from Microsoft and Google. Shares fell during the session and again after hours.

The RIP: $ZM fell 3.9% after hours after closing down 3.7%. Adjusted EPS was $1.55, and revenue was $1.28B vs. $1.27B consensus. Enterprise revenue rose 7.8%, while Q3 adjusted EPS guidance of $1.46-$1.48 trailed the $1.50 estimate.

The Community Read: The $ZM room is 78% bullish, find the disputed profit number ->

STOCKS Foot Locker Kicks Back

Dick’s Sporting Goods, the athletic gear retailer that now owns Foot Locker, reported weaker Q2 results Tuesday and cut its full-year outlook after heavy promotions and soft sneaker launches hit the acquired chain. Shares suffered their biggest percentage decline on record.

The RIP: $DKS sank 30.7% to $124.31 on 14.5x volume. Adjusted EPS was $3.53 vs. $3.76 consensus, and revenue was $5.59B vs. $5.64B. Dick’s comps rose 4.9%, Foot Locker comps fell 3.6%, and full-year sales guidance dropped to $21.9B-$22.2B.

For holders, the 4.9% namesake comp versus Foot Locker’s 3.6% decline makes the integration the whole decision. Management’s next report must show fewer promotions, better launches, and a path from Foot Locker’s drag to the promised synergies. The room treated the selloff like a failed biotech trial, then argued that 30% off an $11B retailer was a gift.

The Community Read: The $DKS room is 98% bullish, inspect the dip-buying math ->

MACRO NEWS Trump’s Portfolio Goes Public  President Donald Trump’s independently managed accounts made 1,051 securities transactions in June, spanning stocks, ETFs, municipal bonds, and Treasuries.  The RIP: Among the 26 disclosed transactions worth at least $1M, the accounts made 18 purchases and 8 sales. The largest move was selling $5M-$25M of $VIG, Vanguard’s dividend-growth ETF.  The accounts added $1M-$5M each of the broad-market $SPY, technology-focused $XLK, industrial-focused $XLI, and commodities-focused $COMT. They also bought Treasury ETFs $GOVT and $IGOV, while selling consumer discretionary ETF $XLY, European stocks through $VGK, and short-term and international bond funds.  The biggest individual-stock purchases were $BRK.B, $V, $MA, and $CTAS on June 18, followed by $FIS and $HD on June 22. The accounts sold $META and $MSI on June 18.

POPS & DROPS Trending Now $CRML +25% | Critical Metals: The rally arrived before the catalyst 14.1K WATCHERS · NEUTRAL · HIGH ACTIVITY Critical Metals surged without a fresh company release as rare-earth developers extended their policy-driven rally around Western supply chains. The neutral room is deciding whether Tanbreez supports the valuation or squeeze chatter outran a development-stage project that still needs financing and execution.  $IBRX +8% | ImmunityBio: The rally could not turn the room bullish 30.1K WATCHERS · BEARISH · NORMAL ACTIVITY ImmunityBio rose after founder Patrick Soon-Shiong said a trial pairing Novartis’ Pluvicto with an IL-15 treatment is being planned, but disclosed no protocol or timing. The bearish room is deciding whether the idea expands Anktiva’s platform or remains another management teaser awaiting clinical details.  $HELP +8% | Helus: The breakout restarted the Phase 3 countdown 8.1K WATCHERS · NEUTRAL · NORMAL ACTIVITY Helus rallied without a fresh filing as traders revisited its new CEO and the Q4 Phase 3 APPROACH readout for depression drug HLP003. The neutral room is weighing a potentially defining clinical catalyst against the dilution risk that follows development-stage biotech into every celebration.

WHAT’S ON DECK Tomorrow’s Top Things

Macro: Personal Consumption Expenditures Price Index (PCE) (8:30 AM ET), GDP Report (8:30 AM ET), Durable goods orders (8:30 AM ET).  Pre-Market Earnings: $CTRM Castor Maritime Inc, $KSS Kohl`s Corp., $TIGR UP Fintech Holding Ltd - ADR, $JKS JinkoSolar Holding Co. Ltd - ADR, $ANF Abercrombie & Fitch Co. - Ordinary Shares - Class A, +5 more.  After-Market Earnings: $NVDA NVIDIA Corp, $CRM Salesforce Inc, $CRWD Crowdstrike Holdings Inc - Ordinary Shares - Class A, $OKTA Okta Inc - Ordinary Shares - Class A, $P Everpure Inc. - Ordinary Shares - Class A, +8 more.